



RESEARCH ARTICLE

THERAPEUTIC FAILURE OF ANTIBIOTICS IN INTENSIVE CARE UNIT: TOWARD BETTER RISK MANAGEMENT AND OPTIMIZED PATIENT CARE (PROSPECTIVE DESCRIPTIVE AND ANALYTICAL STUDY OF 100 CASES)

S. Tougar, S. Alaoui Z. Naghir, C. Quesbaoui and B. Charra

Department of Intensive Care Medicine, Ibn Rochd University Hospital, Faculty of Medicine and Pharmacy of Casablanca, Hassan 2 University, Casablanca, Morocco.

Manuscript Info

Manuscript History

Received: 20 November 2024

Final Accepted: 24 December 2024

Published: January 2025

Key words:-

Therapeutic Failure, Antibiotics, Intensive Care Unit, Mortality

Abstract

Infections in intensive care represent a critical situation where failure of anti-infective therapy, closely linked to high mortality rates, demands rapid detection and appropriate management by intensivists. Early intervention to identify and address treatment failure is therefore essential. This study aimed to determine the incidence of therapeutic failure, identify associated risk factors, and evaluate its prognostic consequences. We conducted a prospective, descriptive, and analytical study over nine months in the medical ICU of CUH Ibn Rochd in Casablanca. All patients receiving antibiotics for suspected or confirmed infections were included, with regular microbiological follow-up. Out of 100 patients, 58 experienced therapeutic failure. The causes were definitively identified in 53.5% of cases, probable in 34.4%, and undetermined in 12.1%. Infectious causes accounted for 41.4%, while non-infectious causes represented 12.1%. Key risk factors included severity at admission, nosocomial infections, atypical pathogens, irregular antibiotic administration, and anemia. A change in antibiotics was found to be an independent protective factor. Mortality was significantly higher in cases of failure ($RR=32.977$). Our findings indicate that better management of therapeutic failures could reduce associated mortality. Further research on a larger sample is needed to refine these conclusions and enhance clinical practices.

Copyright, IJAR, 2025., All rights reserved.

Introduction:-

The discovery of anti-infective agents has radically transformed the management of infections. Despite advances in antibiotic therapy, infections remain a major cause of global mortality¹. In intensive care units, infections are associated with significantly increased mortality, even in the presence of antibiotics². Early and effective antibiotic therapy is essential to prevent the worsening of infections. This therapy is often administered as broad-spectrum treatment during the first 72 hours, followed by adjustments based on microbiological results to target the responsible bacteria and prevent resistance. However, between 4% and 14% of patients exhibit insufficient response to treatment, constituting therapeutic failure^{3,4}.

Antibiotic failure can be categorized into two types: clinical failure, defined by the persistence or worsening of infection symptoms, and microbiological failure, characterized by the continued isolation of initially identified

Corresponding Author:- S. Tougar

Address:- Department of Intensive Care Medicine, Ibn Rochd University Hospital, Faculty of Medicine and Pharmacy of Casablanca, Hassan 2 University, Casablanca, Morocco.

bacteria, regardless of resistance variations. Few studies have investigated the general factors influencing this failure in intensive care settings, although elements such as the frequency of resistant bacteria and the severity of patients are critical considerations.

The overall objective of this study is to determine the incidence of antibiotic failure in intensive care. Additionally, it aims to identify the different etiologies behind therapeutic failure, analyze the factors associated with this failure, and assess its prognostic implications. Finally, the study seeks to propose recommendations for improving antibiotic prescriptions in intensive care settings.

Materials And Methods:-

This is a prospective, single-center, descriptive, and analytical study conducted over nine months in the medical intensive care unit of Ibn Rochd University Hospital in Casablanca. It included adult patients with confirmed or suspected bacterial infections who received antibiotics after initial bacteriological samples were collected. A reassessment was performed after 72 hours of treatment or in cases of suspected failure. Data were recorded and analyzed using EXCEL and SPSS software. Statistical tests, such as the Student's t-test for continuous variables and the Chi-square test for nominal variables, were employed to analyze the results and identify the risk factors for antibiotic failure and mortality.

Results:-

During the study period, among the 100 patients hospitalized and treated for bacterial infections, we identified 58 cases of antibiotic treatment failure, corresponding to an incidence rate of 58%. Among them, 68.96% had persistent infection, while 31.03% had progressive infection. The average age of the patients was 44.14 years, with a standard deviation of 17.82. Male patients predominated, representing 55% of the cases, with a male-to-female ratio of 1.23. The patients were relatively severe, as indicated by a mean SOFA score of 4.8. The average length of stay was 21.14 days, with a standard deviation of 17.38. The combination of two comorbidities was present in 18.96% of cases. Diabetes was the most common comorbidity, found in 27.58% of cases.

The most frequent reason for admission was feverless consciousness disturbances in 35% of cases, followed by febrile consciousness disturbances in 24%, respiratory distress in 19%, and septic shock in 12%. 79.3% of our patients had either fever or hypothermia. The average APACHE II score of our patients increased from 14.71 (standard deviation: 1.767) on admission to 17.02 (standard deviation: 2.51) on the day of failure. 64% of the patients who failed treatment were intubated and ventilated at admission.

Leukocytosis was found in 69% of the patients. CRP was positive in 41% of cases. Chest X-ray showed an infectious focus in 13.79% of cases.

Urine culture (ECBU) was the most frequently performed test, conducted in 81% of cases, with a yield of 11.90%. The highest yield was obtained with PBDP (43.75% positive samples), followed by blood cultures on Sabouraud agar (17.2%). (Table 1)

Prélèvements	n	%(patients)	Positifs n (% prélèvements positifs)
ECBU	47	81	5 (10,63)
PBDP	32	55,2	14 (43,75)
Hémoculture aérobie	34	56,8	5 (14,70)
Ponction lombaire	28	48,3	1 (1/28)
Hémoculture anaérobie	32	55,2	0 (0)
Hémoculture Sabouraud	10	17,2	4(4/10)
PCR Tuberculose dans le LCR	2	3,44	1 (1/2)
Examen de bout de KTC	8	13,8	1 (1/8)
Ecouvillonnage nasopharyngé	3	5,17	1 (1/ 3)

Table1:-Initial microbiological investigations.

Documented infection was identified in 25 patients, representing 43.10%, with 12 pathogens identified. *Acinetobacter baumannii* was the most frequently isolated pathogen, found in 25.58% of the positive samples, followed by *Candida albicans* in 13.95%, and Methicillin-resistant *Staphylococcus aureus* (MRSA), which was isolated in 13.95% of cases (Figure 1).




Figure1:-Proportionsofresistantgerms.

MRSA: methicillin-resistant *Staphylococcus aureus*; MSSA: methicillin-susceptible *Staphylococcus aureus*; H1N1: influenzae virus A subtype H1N1

The notion of having taken an antibiotic during the 2 months prior to admission was found in 24 patients (41.4%). All initial anti-infective prescriptions were probabilistic. Dual therapy was prescribed as first-line treatment in 53% of cases, monotherapy in 26% and triple therapy in 21%. Ceftriaxone was the molecule most frequently prescribed as monotherapy, in 66.7% of our patients. Combination therapy was dominated by Ceftriaxone+Levofloxacin, accounting for 15.51% of cases. The combination Imipenem+Teicoplanin+Amikacin was the most prescribed triple therapy in 8.62% of cases. Seven patients were treated with the antifungal :fluconazole for a confirmed mycotic infection. Five patients were treated with Acyclovir for viral infections, one of which was confirmed. Antibiotic therapy was modified in 27% of prescriptions, with an average delay of 6 days (standard deviation=3.18). 12% were de-escalations and 15% were therapeutic escalations. No prescription were made after a therapeutic window.

The outcome of four patients revealed a mortality rate of. Of these, 72.4% had failed antibiotic therapy, compared with 14.28% of those who had received effective antibiotic treatment. All cases of treatment failure were associated with persistent infections.

All patients with antibiotic failure due to nosocomial infection died. » A detailed analysis of four results enabled us to identify factors predictive of failure, as well as elements associated with a poor prognosis.

Analysis of the factors predictive of antibiotic therapy failure in our series highlighted several decisive elements. Among patient-related factors, severity on admission stood out, including a Glasgow score below 9/15 ($p=0.012$) and a high SOFA score, associated with a significant risk ($p<0.0001$). A low hematocrit ($p=0.046$) was also an important predictive factor. » Mechanical ventilation, whether instituted at admission ($p=0.011$), at the beginning of the antibiotic treatment ($p=0.004$) or after 72 hours ($p=0.000$), as well as central line placement on admission ($p=0.008$), are also correlated with treatment failure. Furthermore, a hypoalbuminemia ($p=0.025$) is significantly associated with failure.

With regard to antibiotic therapy factors, irregular antibiotic use ($p = 0.000$) and failure to modify anti-infective treatment ($p=0.010$) increase the risk of failure. Finally, among germ-related factors, nosocomial infection ($p = 0.024$) was significantly associated with failure, although antibiotic resistance showed no correlation.

We also analyzed factors predictive of poor prognosis. Host included the presence of apyretic consciousness ($p=0.024$). Death was significantly associated with antibiotic failure. ($p<0.0001$), septic shock ($p=0.000$) and the development of hypoalbuminemia ($p=0.039$). Other factors, such as critical condition requiring mechanical ventilation, central line, irregularity of anti-infectives and infection are also correlated with a poor prognosis. In terms of germ-related factors, infection with typical germs ($p=0.001$) was an unfavorable factor. Conversely, persistent infection ($p=0.012$) seems paradoxically to be a protective factor against death.

Discussion:-

The management of anti-infective agents in the ICU remains a major challenge despite its frequency, due to the many factors influencing the infectious process: the germ, the site of infection, host characteristics and choice of anti-infective agent. Treatment failure is a consideration of bacterial resistance, access to the infected site, immune defenses and adjustment of the therapeutic protocol. This definition is complex, as it involves identifying the symptoms and determining when their persistence becomes abnormal.

Since the 1980s, failure has been established for simple contexts, but by resuscitation, these criteria are often inadequate, leaving much to the clinical judgment of the resuscitator.

Defining antibiotic therapy failure:

No consensus definition of treatment failure has yet been published²². Detection of failure is based primarily on clinical criteria, such as persistence or worsening of local and/or general signs of infection despite appropriate antibiotic treatment. Prolonged use of catecholamines may also indicate failure. Time to regression of clinical signs varies according to the pathology: 3 to 6 days for ventilator-associated pneumonia (VAP) and 5 to 6 days for meningitis^{6,7}. Radiological infiltrates disappear on average after 10 days in cases of community-acquired pneumonia⁸.

Biochemical and microbiological criteria such as persistent isolation of the original bacteria in diagnostic samples (with or without modification of the resistance phenotype), can also signal failure.

Procalcitonin is a valuable marker for assessing these situations in the ICU⁵.




Fig. 1:- Algorithm for antibiotic failure and what to do in the event of failure²².

Causes of antibiotic therapy failure

Patient-related failures

In some situations, despite correct diagnosis and treatment, antibiotic therapy may fail, particularly in immunocompromised patients. It is essential to remember that antibiotic support hinders the host's defenses in the eradication of pathogens. Neutropenia and lymphopenia are well-established risk factors for antibiotic failure^{9,10}.

Failure due to delay in antibiotic

The longer the delay, the worse the prognosis, as shown in the study by Kumar et al: each hour's delay in administering the first dose of antibiotics increases mortality by around 7%².

Antibiotic-related failure:

Antibiotic failure can result from a variety of factors.

Unsuitable choice of initial antibiotic:

Unsuitable initial antibiotic therapy is a frequent cause of therapeutic delay, often associated with high mortality, irrespective of the site or severity of the infection¹¹. In the ICU, this situation is exacerbated by the complexity of diagnoses, the diversity of clinical pictures and the wider range of resistance, which can lead to an antibacterial spectrum that is insufficient to cover the germs responsible. In addition, the failure to detect certain pathogens, particularly anaerobic bacteria in polymicrobial infections, is due to inadequate sampling, transport or culture, underlining the importance of systematically performing anaerobic blood cultures¹².

Pharmacodynamic parameters:

The particularities of resuscitation, such as alterations in hepatic and renal function, modify the pharmacokinetic parameters of antibiotics, reducing maximum and minimum plasma concentrations and the area under the curve. These variations can lead to therapeutic failure if doses or administration are not adapted¹³.

Insufficient distribution:

The effectiveness of treatments can also be limited by insufficient diffusion. Insufficient uptake of the antibiotic in infected tissue, depending on its physicochemical properties. By example, macrolides work best intracellularly, while chloramphenicol effectively penetrates the central nervous system.

Inactivation:

Certain drug interactions, such as the formation of inactive complexes during simultaneous infusions, can also reduce antibiotic efficacy. Similarly, purulent media or hypoxia in abscesses diminish the activity of certain agents, such as aminoglycosides and polymyxins¹⁴.

Unsuitable route of administration:

Defects in absorption are another factor in failure, particularly with oral antibiotics administered in the presence of digestive disorders, or in interaction with substances such as antacids, calcium or iron, which reduce their bioavailability¹⁵.

Inappropriate duration of treatment:

Finally, inappropriate duration of treatment, either too short or poorly adhered to, is a well-known cause of failure, often leading to relapse¹⁶.

Bacterial failures:

Pathogen misidentification

Failure of antibiotic therapy, which is often probabilistic, may be due to non-bacterial origin of the infection, particularly in pulmonary, central nervous system or systemic infections in intensive care. In immunocompromised patients, such as those infected with HIV or returning from tropical zones, a wide range of differential diagnoses must be considered in the event of antibiotic therapy failure¹⁷.

Laboratory errors or misinterpretation of microbiological results can also explain failure. This occurs when the germ is difficult to culture, or when diagnostic tests are not sufficiently specific. It is therefore essential to reassess the significance of initial microbiological examinations, taking into account factors such as the type of

sample, its reliability in relation to the infected site, the number of positive samples (particularly for blood cultures), the bacterial count and the pathogenicity of the bacteria isolated. In addition, errors in interpretation of the antibiogram, or lack of precision concerning in vitro and in vivo sensitivity discrepancies, can also lead to therapeutic failures.

Resistance acquisition during treatment:

The acquisition of resistance during treatment is also a key factor in failure. This resistance can arise through several mechanisms, demonstrated by Livermore et al¹⁷. The

Resistance is most common in monotherapy with antibiotics such as penicillins, aminoglycosides and fluoroquinolones, and is particularly notable in bacteria such as *Acinetobacter* spp., *Pseudomonas aeruginosa*, *Serratia* spp. and *Enterobacteriaceae*. Intensive care patients, especially those on mechanical ventilation, are more likely to acquire resistance during treatment¹⁸.

Insufficient bactericidal activity

Bactericidal failure may occur mainly in patients with systemic or local immunodeficiency. In the case of the **inoculum effect**, failure may occur if the antibiotic dosage is insufficient to reach infectious foci with a high microbial inoculum, such as in abdominal suppurations. A purulent collection may contain more than 10^9 bacteria/ml of pus, well above the concentration used to determine the minimum inhibitory concentration (MIC) during antibiotic susceptibility testing (10^5), making the latter falsely underestimated.

Quiescent bacteria, which have a slow metabolism and can survive for years in sites that are difficult to access with antibiotics, are also a factor in failure. These bacteria are insensitive to the majority of antibiotics, which act primarily on the active metabolisms. This is particularly true for chronic osteomyelitis, chronic pyelonephritis, and endocarditis caused by bacteria of the HACEK group.

Failures related to the infected site:

Undrained purulent retention is a factor in therapeutic failure, especially when the purulent focus measures more than 5 cm, whether initial or due to a complication. If this type of focus is not managed surgically, it is associated with a poor outcome¹⁹.




Figure2:- There are multiple strategies that microbes use to develop resistance to antimicrobial drugs²³.

The presence of foreign material, such as a valve prosthesis, pacemaker, intravascular or dialysis catheter, urinary catheter, or orthopedic material, increases the risk of antibiotic therapy failure. These devices promote germ adhesion and the formation of a protective polysaccharide biofilm, making infection more difficult to treat²⁰.

Secondary locations, such as septic metastases, must be systematically investigated in the event of failure, particularly in the case of bacteremia. They complicate up to 30.3% of *Staphylococcus aureus* bacteremias²¹.

Analysis of four results:

Failure of antibiotic therapy in the ICU is a frequent phenomenon, as highlighted by our study, which was conducted independently to ensure impartial results. Three points: The main findings were: high frequency of failure, resistance of germs to initial probabilistic antibiotic therapy as the main cause, and increased mortality in the event of failure. An in-depth analysis of the microbiological results was carried out.

Our study identified *Acinetobacter baumannii* as the most frequently isolated germ (25%), responsible for persistent infections in the ICU, in line with the literature^{24,25}. This germ shows marked resistance to initial antibiotic therapy^{26,27}, underlining the importance of thorough microbiological evaluation to adjust treatment. Less common germs, such as mycoses (13%), tuberculosis (2.32%) and the H1N1 virus (2.32%), were also present.%, were also identified as causes of primary infections. The low use of blood cultures on Sabouraud medium (17%) and of viral tests (5%) could explain the low rates of infection diagnosis and associated failures. The high prevalence of fungal infections may be linked to the high proportion of diabetics in our population (27.6%)²⁸.

As for the etiologies of antibiotic failure, persistent infections predominated (55.18%), mainly due to resistance to initial probabilistic antibiotics³⁰. Irregular use of antibiotics (58.62%) and their administration prior to admission (41%) also contributed to this failure. In contrast to other studies reporting a high incidence of nosocomial infections²⁹, our cohort showed a higher prevalence of persistent infections.

In terms of prognosis, overall mortality was 48%, with an alarming 72.4% in patients with treatment failure. This figure is higher than the rates reported by Orban et al³¹ and Kyan et al³², probably due to factors such as anemia (86%) and undernutrition (68.2%)³⁴. The prevalence of *Acinetobacter baumannii*, implicated in 29% of bacteremia deaths³³, also contributes to these results.

A correlation has been observed between clinical severity on admission (high APACHE II score, anemia, mechanical ventilation, central line) and the risk of antibiotic failure. Furthermore, nosocomial infection remains a major risk factor³⁵. Finally, failure to adhere to antibiotic administration schedules significantly increases the risk of failure (multiplied by 17.725), highlighting the importance of strict adherence to therapeutic protocols³⁶.

Conclusion:-

Our study identified several risk factors for antibiotic treatment failure, including patient severity on admission, low hemoglobin, nosocomial infection and irregular intake of anti-infective agents. Treatment failure is often associated with high mortality, requiring early identification and management. The detection of resistant or unusual germs relies on repeated microbiological investigations.

In developing countries, the regularity of anti-infective treatment plays a crucial role in optimizing clinical outcomes. In order to better manage antibiotic failures, it is essential to strengthen nosocomial infection prevention and improve microbiological diagnosis by using advanced tools such as PCR tests and procalcitonin assays. Close collaboration with microbiology laboratories is essential to monitor microbial ecology and adapt therapeutic strategies accordingly. In addition, complementary measures in resuscitation, such as nutrition management, hygiene and regular audits, are also necessary to reduce mortality and improve clinical outcomes.

References:-

1. WHO Infectious diseases report Text only [Internet 2011 Available on:
2. <http://www.who.int/infectious-disease-report/idr99-english/pages/textonly.html>

3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. *Critical Care Medicine*. 2006;34(6):1589- 1596. doi:10.1097/01.ccm.0000217961.75225.e9
4. Fang G-D, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM. New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for Therapy. *Medicine*. 1990;69(5):307-316. doi:10.1097/00005792-199009000-00004
6. RUIZ M, EWIG S, MARCOS M, MARTINEZ J, ARANCIBIA F, MENSA J, TORRES A. Etiology of Community-Acquired Pneumonia. *American Journal of Respiratory and Critical Care Medicine*. 1999;160(2):397-405. doi:10.1164/ajrccm.160.2.9808045
8. Sotillo-Díaz J, Bermejo-López E, García-Olivares P, Peral-Gutiérrez J, Sancho-González M, Guerrero-Sanz J. Role of plasma procalcitonin in the diagnosis of ventilator-associated pneumonia: Systematic review and metaanalysis. *Medicina Intensiva (English Edition)*. 2014;38(6):337-346. doi:10.1016/j.medine.2013.07.004
10. Dennessen PJW, van der VEN AJAM, Kessels AGH, Ramsay G, BontenMJM. Resolution of Infectious Parameters after Antimicrobial Therapy in Patients with Ventilator-associated Pneumonia. *Am J Respir Crit Care Med*. May 2001; 163(6): 1371-1375.
11. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *American Journal of Respiratory and Critical Care Medicine*. 2005;171(4):388-416. doi:10.1164/rccm.200405-644st
12. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study .Moussaoui R el, de Borgie CAJM, van den Broek P, Hustinx WN, Bresser P, van den Berk GEL, et al. 6 Oct 2006; 332(7554): 1355.
13. Risk factors for adverse outcomes and multidrug-resistant Gram- negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. Poon LM, Jin J, Chee YL, Ding Y, Lee YM, Chng WJ, et al. *Singapore Med J*. nov 2012; 53(11): 720-725.
14. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, et al. *PloS One*. 2011; 6(7): e20436.
15. Efficacy of adequate early antibiotic therapy in ventilator- associated pneumonia: influence of disease severity. Clec'h C, Timsit J-F, De Lassence A, Azoulay E, Alberti C, Garrouste-Orgeas M, et al. *Intensive Care Med*. juill 2004; 30(7): 1327-1333
16. Reemergence of anaerobic bacteremia. *Clin Infect Dis Off Publ Infect Dis Soc Am* Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. 1 Apr 2007; 44(7): 895-900.
17. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. *Antimicrob Agents Chemother*. feb 2012; 56(2): 1065-1072.
18. Peripheral inactivation of gentamicin. Vaudaux P. *J Antimicrob Chemother*. 1 Jan 1981; 8(suppl A): 17- 25.
19. Comparative study of the influence of Ca²⁺ on absorption parameters of ciprofloxacin and ofloxacin. Navarro AS, Cabarga MM, Hurlé AD-G. *J Antimicrob Chemother*. 7 Jan 1994; 34(1): 119-125.
20. Duration of antibiotic therapy for severe infections in intensive care. Wolff M, Chastre J. *Réanimation*. June 2006; 15(3): 168-175.
21. Emerging multi-resistant and highly resistant bacteria: definition and resistance of epidemiological interest. Baquer, F., Giraudon, E., & Jehl, F. *Revue Francophone des Laboratoires*, 2021(537), 28-36.
22. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Fish DN, Piscitelli SC, Danziger LH. *Pharmacotherapy*. June 1995; 15(3): 279-291.
24. Outcome of medical treatment of bacterial abscesses without therapeutic drainage: review of cases reported in the literature. Bamberger DM. *Clin Infect Dis Off Publ Infect Dis Soc Am*. sept 1996; 23(3): 592- 603.
25. Biofilm formation: a clinically relevant microbiological process. Donlan RM. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 15 Oct 2001; 33(8): 1387- 1392.
26. Outcome of *Staphylococcus aureus* bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, et al. *Clin Infect Dis Off Publ Infect Dis Soc Am*. Sept 1998; 27(3): 478-486
27. When antibiotic treatment fails. Bassetti, M., Montero, J. G., & Paiva, J. A. (2018). *Intensive Care Medicine*, 44(1), 73-75.

28. Nina .P , Mark .S , Anh-Hue Thi Tu , Brian M. Forster , Philip .L, Allied Health Microbiology American Society of Microbiology (ASM) Partnership 2019.
29. High Prevalence of Multidrug-Resistant Nonfermenters in Hospital-acquired Pneumonia in Asia. Chung DR, Song J-H, Kim SH, Thamlikitkul V, Huang S-G, Wang H, et al. Am J Respir Crit Care Med. 15 Dec 2011; 184(12): 1409-1417.
30. The Causes and Treatment Outcomes of 91 Patients with Adult Nosocomial Meningitis. Kim H-I, Kim S-W, Park G-Y, Kwon E-G, Kim H-H, Jeong J-Y, et al. Korean J Intern Med. 2012; 27(2): 171.
31. . ICU-Associated *Acinetobacter baumannii* Colonization/Infection in a High HIV-Prevalence Resource- Poor Setting. Ntusi NBA, Badri M, Khalfey H, Whitelaw A, Oliver S, Piercy J, et al. PLoS ONE. Dec 27, 2012; 7(12): e52452.
32. Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.).
33. Les candidoses vulvovaginales : facteurs de risque et particularités cliniques et mycologiques. Anane S, Kaouech E, Zouari B, Belhadj S, Kallel K, Chaker E. J Mycol Médicale J Med Mycol. mars 2010; 20(1): 36- 41
34. Incidence of nosocomial bacterial infections. Abderrahim Harouchi Children's Hospital, CHU Ibn Rochd, Casablanca, Morocco. Chemsî M, Chahid I, Lehlîmi M, Aalloula O, Zerouali K, Habzi A, et al. J Pédiatrie Puériculture. feb 2013; 26(1): 11-18.
35. High Prevalence of Multidrug-Resistant Nonfermenters in Hospital-acquired Pneumonia in Asia. Chung DR, Song J-H, Kim SH, Thamlikitkul V, Huang S-G, Wang H, et al. Am J Respir Crit Care Med. 15 Dec 2011; 184(12): 1409-1417
36. The importance of early diagnosis of sepsis in severe burned patients: outcomes of 100 patients. Orban C, Tomescu D. Chir Buchar Rom 1990
37. Variation exists in rates of admission to intensive care units for heart failure patients across hospitals in the United States. Safavi KC, Dharmarajan K, Kim N, Strait KM, Li S-X, Chen SI, et al. Circulation. Feb 26, 2013; 127(8): 923-929.
38. Impact of Appropriate Antimicrobial Therapy on Mortality Associated With *Acinetobacter baumannii* Bacteremia: Relation to Severity of Infection. Lee Y-T, Kuo S-C, Yang S-P, Lin Y-T, Tseng F-C, Chen T-L, et al.
39. al. Clin Infect Dis. 15 Jul 2012; 55(2): 209-215.
40. Association of hemoglobin concentration and mortality in critically ill patients with severe traumatic brain injury. Sekhon MS, McLean N, Henderson WR, Chittock DR, Griesdale DE. Crit Care Lond Engl. 20 Jul 2012; 16(4): R128.
41. β -lactam allergy: clinical implications and costs Satta G, Hill V, Lanzman M, Balakrishnan I. Clin Mol Allergy. 27 Nov 2013; 11(1): 2.
42. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant *Staphylococcus aureus*: vancomycin and linezolid. Stein GE, Wells EM. Curr Med Res Opin. March 2010; 26(3): 571-588.